We designed and synthesised a series of new cationic lipids based on spermine linked to various hydrophobic anchors. These lipids could be potentially useful for the preparation of stable cationic liposomes intended for the construction of drug targeting systems applicable in the field of anticancer/antiviral therapy, vaccine carriers, and vectors for the gene therapy. Low in vitro toxicity was found for these compounds, especially for LD1, in several cell lines. The delivery of both a fluorescence marker (calcein) and antiviral drugs into cells has been achieved owing to a large extent of internalization of cationic liposomes (labelled by Lyssamine-Rhodamine PE or fluorescein-PE) as demonstrated by fluorescent microscopy and quantified by flow cytometry. The bovine herpes virus type 1 (BHV-1) virus infection in vitro model using MDBK cells was employed to study the effect of the established antiviral drug HPMPC (Cidofovir®) developed by Prof. A. Holý. Inhibition of BHV-1 virus replication was studied by quantitative RT-PCR and confirmed by both Hoffman modulation contrast microscopy and transmission electron microscopy. We found that in vitro antiviral activity of HPMPC was significantly improved by formulation in cationic liposomes, which decreased the viral replication by about 2 orders of magnitude.

Veterinary Research Institute Department of Toxicology Pharmacology and Immunotherapy Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc13000950

003      

CZ-PrNML

005      

20130204120239.0

007      

ta

008      

130108s2012 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.jconrel.2012.01.040 $2 doi

035    __

$a (PubMed)22326403

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Korvasová, Zina $u Veterinary Research Institute, Department of Toxicology, Pharmacology and Immunotherapy, Brno, Czech Republic.

245    10

$a Antiviral effect of HPMPC (Cidofovir®), entrapped in cationic liposomes: in vitro study on MDBK cell and BHV-1 virus / $c Z. Korvasová, L. Drašar, J. Mašek, P. Turánek Knotigová, P. Kulich, J. Matiašovic, K. Kovařčík, E. Bartheldyová, Š. Koudelka, M. Škrabalová, AD. Miller, A. Holý, M. Ledvina, J. Turánek,

520    9_

$a We designed and synthesised a series of new cationic lipids based on spermine linked to various hydrophobic anchors. These lipids could be potentially useful for the preparation of stable cationic liposomes intended for the construction of drug targeting systems applicable in the field of anticancer/antiviral therapy, vaccine carriers, and vectors for the gene therapy. Low in vitro toxicity was found for these compounds, especially for LD1, in several cell lines. The delivery of both a fluorescence marker (calcein) and antiviral drugs into cells has been achieved owing to a large extent of internalization of cationic liposomes (labelled by Lyssamine-Rhodamine PE or fluorescein-PE) as demonstrated by fluorescent microscopy and quantified by flow cytometry. The bovine herpes virus type 1 (BHV-1) virus infection in vitro model using MDBK cells was employed to study the effect of the established antiviral drug HPMPC (Cidofovir®) developed by Prof. A. Holý. Inhibition of BHV-1 virus replication was studied by quantitative RT-PCR and confirmed by both Hoffman modulation contrast microscopy and transmission electron microscopy. We found that in vitro antiviral activity of HPMPC was significantly improved by formulation in cationic liposomes, which decreased the viral replication by about 2 orders of magnitude.

650    _2

$a zvířata $7 D000818

650    _2

$a antivirové látky $x aplikace a dávkování $x farmakologie $7 D000998

650    _2

$a kationty $7 D002412

650    _2

$a skot $7 D002417

650    _2

$a buněčné kultury $7 D018929

650    _2

$a buněčné linie $7 D002460

650    _2

$a viabilita buněk $x účinky léků $7 D002470

650    _2

$a cytopatogenní efekt virový $7 D003588

650    _2

$a cytosin $x aplikace a dávkování $x analogy a deriváty $x farmakologie $7 D003596

650    _2

$a nosiče léků $x chemie $7 D004337

650    _2

$a bovinní herpesvirus 1 $x účinky léků $x fyziologie $7 D007242

650    _2

$a ledviny $x cytologie $x virologie $7 D007668

650    _2

$a lipidy $x chemie $7 D008055

650    _2

$a liposomy $7 D008081

650    _2

$a fluorescenční mikroskopie $7 D008856

650    _2

$a organofosfonáty $x aplikace a dávkování $x farmakologie $7 D063065

650    _2

$a kvantitativní polymerázová řetězová reakce $7 D060888

650    _2

$a replikace viru $x účinky léků $7 D014779

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Drašar, Lukáš

700    1_

$a Mašek, Josef

700    1_

$a Turánek Knotigová, Pavlína

700    1_

$a Kulich, Pavel

700    1_

$a Matiašovic, Ján

700    1_

$a Kovařčík, Kamil

700    1_

$a Bartheldyová, Eliška

700    1_

$a Koudelka, Štěpán

700    1_

$a Škrabalová, Michaela

700    1_

$a Miller, Andrew D

700    1_

$a Holý, Antonín

700    1_

$a Ledvina, Miroslav

700    1_

$a Turánek, Jaroslav

773    0_

$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 160, č. 2 (2012), s. 330-8

856    41

$u https://pubmed.ncbi.nlm.nih.gov/22326403 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20130108 $b ABA008

991    __

$a 20130204120410 $b ABA008

999    __

$a ok $b bmc $g 963732 $s 799114

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2012 $b 160 $c 2 $d 330-8 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621

LZP    __

$a Pubmed-20130108